Posters

      Reduced effects of aqueous aerosol extract from THS2.2, a candidate Modified Risk Tobacco Product on the adhesion of monocytic cells to human coronary arterial endothelial cells

      Poussin, C.; Laurent, A.; Peitsch, M. C.; Hoeng, J.; De Leon, H.

      Conference date
      Nov 11, 2015
      Conference name
      American College of Toxicology (ACT) 2015
      Link to more information
      Topic
      Summary

      Smoking is a major risk factor for the development of cardiovascular diseases. Modified risk tobacco products (MRTP) are designed to reduce smoking-related health risks. The present study aimed to evaluate the impact of THS2.2, a candidate heat-notburn technology-based MRTP, compared with a reference cigarette (3R4F), on the adhesion of monocytic cells to human coronary arterial endothelial cells (HCAECs), a critical stage in atherosclerosis development, using a functional in vitro adhesion assay combined with systems toxicology. HCAECs were treated for 4h with conditioned media of human monocytic mono mac 6 (MM6) cells preincubated with low or high concentrations of aqueous extracts from THS2.2 aerosol or 3R4F smoke for 2h (indirect treatment), unconditioned media (direct treatment), or fresh aqueous extract (fresh direct treatment). Previous results showed that aqueous 3R4F smoke extract induced the adhesion of MM6 cells to HCAECs via distinct direct and indirect concentrationdependent mechanisms. Leveraging the same experimental and computational framework, significant reduced effects of aqueous THS2.2 aerosol extract on MM6 cell- CAEC adhesion were measured, also supported by markedly diminished molecular changes such as gene expression in both endothelial and monocytic cells. A shift towards 10 and 20 times higher concentrations of aqueous THS2.2 aerosol extract was required to observe similar effects as the ones measured with 3R4F in both fresh direct and indirect exposure modes, respectively. In conclusion, our in vitro systems toxicology investigations revealed reduced effects ofTHS2.2, a candidate MRTP, on monocytic cell-endothelial cell adhesion compared with a reference cigarette.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.